DGX Cash & equivalents
Cash & equivalents at Quest Diagnostics fell to $420M in fiscal 2025, from $549M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1022079 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$420M
FY2024 $549M
HIGH$872M FY2021
LOW$315M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $420M | $-129M |
| FY2024 | $549M | $-137M |
| FY2023 | $686M | +$371M |
| FY2022 | $315M | $-557M |
| FY2021 | $872M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · DGX company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.